SCHW:NYSECharles Schwab Corporation (The) Analysis
Data as of 2026-05-23 - not real-time
$90.15
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
The Charles Schwab Corporation is trading at $90.15, well below its 20‑day SMA of 90.72, 50‑day SMA of 92.65 and 200‑day SMA of 95.40, indicating a short‑term bearish bias. However, the MACD histogram is positive (0.15) and volume is increasing, hinting at emerging momentum. The stock enjoys a solid dividend yield of 1.42% with a modest payout ratio of 22%, supporting income‑focused investors. Fundamentally, SCHW delivers robust profitability—operating margin near 49% and ROE around 19%—and a DCF‑derived fair value of $125, implying roughly 28% upside versus the current price. Recent analyst upgrades, including Barclays raising its target to $127, reinforce the upside narrative, while a few dissenting views keep the consensus at a “Buy.”
Given the low beta (~0.68) and strong cash position, the stock presents a compelling blend of growth and value characteristics, making it attractive for medium‑ to long‑term investors despite the near‑term technical headwinds.
Given the low beta (~0.68) and strong cash position, the stock presents a compelling blend of growth and value characteristics, making it attractive for medium‑ to long‑term investors despite the near‑term technical headwinds.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price is near the identified support level of $87.61
- Bearish technical backdrop with price below key SMAs
- Increasing volume and a positive MACD histogram suggest potential reversal
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- DCF fair value of $125 implies ~28% upside
- Analyst median price target of $118 and recent target raises
- Strong revenue growth (15.8%) and high operating margins
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Sustainable dividend yield of 1.4% with low payout ratio
- Robust cash position and low beta reduce market risk
- Consistent profitability and ROE near 19% support long‑term compounding
Key Metrics & Analysis
Financial Health
Revenue Growth15.80%
Profit Margin37.99%
P/E Ratio17.9
ROE19.08%
ROA1.97%
Debt/Equity120.77
P/B Ratio3.7
Op. Cash Flow$10.3B
Industry P/E16.8
Technical Analysis
TrendBearish
RSI45.9
Support$87.61
Resistance$93.43
MA 20$90.72
MA 50$92.65
MA 200$95.40
MACDBullish
VolumeIncreasing
Fear & Greed Index91.61
Valuation
Fair Value$125.02
Target Price$115.85
Upside/Downside28.51%
GradeUndervalued
TypeBlend
Dividend Yield1.42%
Risk Assessment
Beta0.68
Volatility32.90%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.